Clinical and Molecular Hepatology

Search

Close

Most cited

Most-cited are based on citations from 2020 ~ 2022.

Original Articles Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim
Clin Mol Hepatol. 2020;26(2):209-215.
Guideline KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho
Clin Mol Hepatol. 2021;27(3):363-401.
Reviews Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clin Mol Hepatol. 2020;26(4):411-429.
Novel biomarkers for the management of chronic hepatitis B
Takako Inoue, Yasuhito Tanaka
Clin Mol Hepatol. 2020;26(3):261-279.
Application of transient elastography in nonalcoholic fatty liver disease
Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2020;26(2):128-141.
Guideline KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Clin Mol Hepatol. 2020;26(2):83-127.
Reviews Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Chung-Feng Huang, Ming-Lung Yu
Clin Mol Hepatol. 2020;26(3):251-260.
Original Articles Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim
Clin Mol Hepatol. 2020;26(3):340-351.
Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard
Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani
Clin Mol Hepatol. 2020;26(1):54-59.
Reviews From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clin Mol Hepatol. 2021;27(2):257-269.
Original Articles Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Na Young Lee, Min Jea Shin, Gi Soo Youn, Sang Jun Yoon, Ye Rin Choi, Hyeong Seop Kim, Haripriya Gupta, Sang Hak Han, Byoung Kook Kim, Do Yup Lee, Tae Sik Park, Hotaik Sung, Byung Yong Kim, Ki Tae Suk
Clin Mol Hepatol. 2021;27(1):110-124.
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol. 2020;26(4):506-515.
Reviews Managing liver cirrhotic complications: Overview of esophageal and gastric varices
Cosmas Rinaldi Adithya Lesmana, Monica Raharjo, Rino A. Gani
Clin Mol Hepatol. 2020;26(4):444-460.
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
Theresa J. Hydes, Sujan Ravi, Rohit Loomba, Meagan E. Gray
Clin Mol Hepatol. 2020;26(4):383-400.
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future
Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai
Clin Mol Hepatol. 2021;27(1):70-80.
Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma
Yuchen Liu, Xiaohui Wang, Yingzi Yang
Clin Mol Hepatol. 2020;26(4):742-750.
Autophagy and liver cancer
Xiaojuan Chao, Hui Qian, Shaogui Wang, Sam Fulte, Wen-Xing Ding
Clin Mol Hepatol. 2020;26(4):606-617.
Reviews Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Clin Mol Hepatol. 2020;26(2):155-162.
Original Articles Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon
Clin Mol Hepatol. 2021;27(1):157-174.
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol. 2020;26(4):516-528.
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Cheol-Hyung Lee, Yun Bin Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Clin Mol Hepatol. 2020;26(3):328-339.
Reviews Extrahepatic manifestations of hepatitis E virus: An overview
Fotios S. Fousekis, Ioannis V. Mitselos, Dimitrios K. Christodoulou
Clin Mol Hepatol. 2020;26(1):16-23.
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease
Erica Jennison, Christopher D. Byrne
Clin Mol Hepatol. 2021;27(1):22-43.
Original Articles Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway
Seulki Lee, Eun Ji Choi, Eun Ju Cho, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Clin Mol Hepatol. 2020;26(4):529-539.
The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma
Kanghyug Choi, Hee Yoon Jang, Joong Mo Ahn, Sung Ho Hwang, Jung Wha Chung, Yun Suk Choi, Jin-Wook Kim, Eun Sun Jang, Gwang Hyeon Choi, Sook-Hyang Jeong
Clin Mol Hepatol. 2020;26(4):492-505.
Reviews Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2020;26(4):461-475.
Original Articles Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park
Clin Mol Hepatol. 2020;26(4):562-576.
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea
Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim
Clin Mol Hepatol. 2020;26(1):24-32.
Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)
Programmed cell death in alcohol-associated liver disease
Tatsunori Miyata, Laura E. Nagy
Clin Mol Hepatol. 2020;26(4):618-625.
Reviews Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
Clin Mol Hepatol. 2021;27(3):402-412.

Go to Top